Physician profile
Roberta S Rose
NPI 1831190248
$12,703.19
in general payments reported to CMS, 2019-2025
48 companies · $984 in 2025
The $984 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,551 · 2020: $739 · 2021: $5,333 · 2022: $1,256 · 2023: $1,516 · 2024: $1,325 · 2025: $984.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,825.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,824.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $4,060.21 | 2020-2021 | |
| Abbvie INC. | $752.21 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Kyowa Kirin, INC. | $602.93 | 2019-2024 | Nourianz |
| Novartis Pharmaceuticals Corporation | $504.00 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $490.75 | 2019-2025 | Nuplazid |
| Teva Pharmaceuticals USA, INC. | $482.48 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Eisai INC. | $476.68 | 2019-2025 | |
| Emd Serono, INC. | $369.59 | 2019-2025 | Mavenclad |
| Mdd US Operations, LLC | $363.59 | 2019-2023 | Apokyn |
| Lilly USA, LLC | $336.65 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Amneal Pharmaceuticals LLC | $302.29 | 2019-2025 | Rytary, Crexont |
| Genzyme Corporation | $275.51 | 2019-2022 | |
| Amgen INC. | $270.25 | 2019-2022 | |
| Sk Life Science, INC. | $260.60 | 2020-2025 | |
| Pfizer INC. | $256.50 | 2021-2025 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $247.40 | 2019-2025 | Rexulti, Vyepti |
| Otsuka America Pharmaceutical, INC. | $242.11 | 2023-2025 | Rexulti, Nuedexta |
| Argenx US, INC. | $234.78 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Upsher-Smith Laboratories LLC | $208.91 | 2019-2023 | |
| Sunovion Pharmaceuticals INC. | $177.62 | 2020-2022 | |
| Ucb, INC. | $171.84 | 2019-2025 | Briviact, Zilbrysq, Rystiggo |
| Avanir Pharmaceuticals, INC. | $133.27 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $119.10 | 2020-2024 | Ingrezza |
| Adamas Pharmaceuticals, INC. | $116.29 | 2019-2021 | |
| Corium, LLC | $108.04 | 2022-2023 | Adlarity |
| Biogen, INC. | $102.44 | 2020-2023 | Vumerity, Avonex, Plegridy |
| Janssen Pharmaceuticals, INC | $97.52 | 2021-2022 | |
| Csl Behring | $96.50 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $89.92 | 2023 | Aptiom |
| Acorda Therapeutics, INC | $88.13 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $86.74 | 2022 | |
| Ge Healthcare | $86.18 | 2019 | |
| Ani Pharmaceuticals, INC. | $60.98 | 2025 | Purified Cortrophin Gel |
| Axsome Therapeutics, INC. | $54.82 | 2025 | Symbravo |
| Neurelis, INC. | $49.30 | 2021-2023 | Valtoco |
| Allergan, INC. | $41.78 | 2019-2021 | |
| Celgene Corporation | $37.03 | 2021 | |
| Genentech USA, INC. | $32.64 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $29.85 | 2020-2021 | |
| Catalyst Pharmaceuticals, INC. | $27.64 | 2021 | |
| Supernus Pharmaceuticals, INC. | $26.39 | 2020-2022 | |
| Greenwich Biosciences, INC. | $25.16 | 2021 | |
| Vertical Pharmaceuticals, LLC | $21.70 | 2020 | |
| Almatica Pharma LLC | $20.89 | 2021 | |
| C2n Diagnostics, LLC | $18.25 | 2025 | Precivityad2 |
| Alexion Pharmaceuticals, INC. | $17.54 | 2019 | |
| Livanova USA, INC. | $14.77 | 2022 | |
| Arbor Pharmaceuticals, INC. | $13.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberta Rose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.